Human Oncology & Pathogenesis Program

The Sarat Chandarlapaty Lab

Share
Print
Back to Top

Research

Pictured: Sarat Chandarlapaty
Sarat Chandarlapaty, MD, PhD

My lab focuses on understanding the regulation of growth factor signal transduction pathways that are aberrantly activated in cancers, with a focus on those implicated in breast cancer pathogenesis.

View Lab Overview

Chandarlapaty Lab

Featured News

In the Lab
Pictured: Sarat Chandarlapaty
Researchers Identify Mutations that Cause Some Breast Cancers to Resist Treatment

In the Clinic
Hand in surgical glove holding up small beaker of blood.
Liquid Biopsy Shown to Be Effective in Assessing Response to Breast Cancer Drugs

Publications

Razavi P, Dickler MN, Shah PD, Toy W, Brown DN, Won HH, Li BT, Shen R, Vasan N, Modi S, Jhaveri K, Caravella BA, Patil S, Selenica P, Zamora S, Cowan AM, Comen E, Singh A, Covey A, Berger MF, Hudis CA, Norton L, Nagy RJ, Odegaard JI, Lanman RB, Solit DB, Robson ME, Lacouture ME, Brogi E, Reis-Filho JS, Moynahan ME, Scaltriti M, Chandarlapaty S. (2020). Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nat Cancer, Mar;1(4):382–393.

Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C, Hsieh W, Sanchez-Vega F, Brown DN, Da Cruz Paula AF, Morris L, Selenica P, Eichenberger E, Shen R, Schultz N, Rosen N, Scaltriti M, Brogi E, Baselga J, Reis-Filho JS, Chandarlapaty S. (2018). Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. Cancer Cell, Dec;34(6):893-905.

Will M, Qin AC, Toy W, Yao Z, Rodrik-Outmezguine V, Schneider C, Huang X, Monian P, Jiang X, de Stanchina E, Baselga J, Liu N, Chandarlapaty S*, Rosen N.* (2014). Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. Cancer Discov, Mar;4(3):334-47.

Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA, Hudis C, Chen D, Taran T, Hortobagyi G, Greene G, Berger M, Baselga J, Chandarlapaty S. (2013). ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet, Dec;45(12):1439-45.

Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder P.K, Baselga J, Rosen N. (2011). AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell, Jan;19(1):58-71.

View All Publications

People

Pictured: Sarat Chandarlapaty

Sarat Chandarlapaty, MD, PhD

  • Physician-scientist Sarat Chandarlapaty studies the regulation of growth factor signaling networks in cancer.
  • MD, Wake Forest School of Medicine
  • PhD, University of North Carolina
[email protected]
Email Address
View physician profile
Physician profile

Members

Yanyan Cai
Isabella Del Priore
Isabella Del Priore

Research Technician

Madeline Dorso
Madeline Dorso

Graduate Student

Avantika Gupta
Avantika Gupta

Research Scholar

Seema Irani
Seema Irani
Rei Kudo
Rei Kudo
Qing Li
Qing Li

Research Fellow

Bo Liu, Research Associate
Bo Liu

Research Associate

Payal Patel

Graduate Student

Ramya Segu Rajappachetty
Ramya Segu Rajappachetty

Research Technician Sr.

Hong Shao
Alison Smith
Alison Smith

Graduate Student

Antonio Strillacci
Antonio Strillacci

Research Fellow

Lab Alumni
Trusha Bhatt
Trusha Bhatt

Research Technician

Mayur Gadiya
Mayur Gadiya

Graduate Student

Kinisha Gala
Kinisha Gala

Scientist at University of California Los Angeles, Los Angeles, CA

Zhiqiang Li
Zhiqiang Li

Research Fellow

Shraddha Pancholi
Shraddha Pancholi

Research Secretary

Weiyi Toy
Weiyi Toy

Research Fellow

Sharmeen Uddin
Sharmeen Uddin

Research Technician

ChengCheng Yang
ChengCheng Yang

Graduate Research Assistant

Lab Affilations

Achievements

  • Clinical Investigator Award, Damon Runyon Cancer Research Foundation (2012)
  • Young Investigator Award, American Society of Clinical Oncology (2007)
  • Fellow in Biomedical Research, The Dana Foundation (2006)

Open Positions

Career Opportunities

Apply now

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Sarat Chandarlapaty discloses the following relationships and financial interests:

  • Breast Cancer Research Foundation
    Provision of Services
  • Bristol-Myers Squibb
    Provision of Services
  • Eli Lilly and Company
    Provision of Services
  • Global Breast Cancer Conference
    Provision of Services
  • National Comprehensive Cancer Network
    Provision of Services
  • Novartis
    Provision of Services
  • Paige.AI, Inc.
    Provision of Services
  • Revolution Medicines
    Provision of Services
  • Sermonix Pharmaceuticals, LLC
    Provision of Services

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures